Talphera, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 1.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 53.46M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Feds...